Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label Extended Access Program of Lenalidomide Plus Low-dose Dexamethasone in Chinese Subjects With Relapsed/Refactory Multiple Myeloma Who Participated in Study CC-5013-MM-021 for at Least One Year.

NCT02348528 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02348528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02348528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label Extended Access Program of Lenalidomide Plus Low-dose Dexamethasone in Chinese Subjects With Relapsed/Refactory Multiple Myeloma Who Participated in Study CC-5013-MM-021 for at Least One Year.
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
September 11, 2012
Completion date
September 29, 2016
Enrollment
65 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma